The FDA’s peptide vote could create telehealth’s next multibillion-dollar market
As regulators weigh whether pharmacies can legally compound wellness peptides, companies are preparing for a repeat of the GLP-1 boom—only this time with even murkier science.
Comments 0
Log in to join the conversation.
No comments yet. Be the first to share your thoughts!